ARS PHARMACEUTICALS INC
SPRYNASDAQ๐ #3106 by market capEarnings Nov 17 ยท PostUS Equity
$3.65โผ $0.08 (โ2.14%)
๐
Pre-market$3.66โฒ 0.27%Regular close ยท extended-hours price shownTrack SPRY
Get earnings, price moves & breaking news on Telegram
24hโผ 2.1%
7dโผ 15.3%
14dโผ 9.9%
30dโผ 17.2%
ytdโผ 68.7%
1yโผ 59.3%
๐ฆMarket Cap
$363M
Small Cap
๐Revenue Growth (YoY)
4.1%
Slowing
๐Gross Margin
71.4%
High
๐ตFCF Margin
โ
โ๏ธP/S Ratio
3.1x
Fair
Otter Score
64
Fair
ARS PHARMACEUTICALS INC
SPRYAnalyst Ratings
Price
$3.65
Total
10
Raised
0
Lowered
6
Avg PT
$15.00
H / L
$15 / $15
| Institution | Action | Rating | Date | Upside | |
|---|---|---|---|---|---|
Leerink Partners | Reiterated | Outperform | 2026-08-13 | $15.00 | +311.00% |
Cantor Fitzgerald | Reiterated | Overweight | 2026-05-28 | $30.00 | +721.90% |
Raymond James | Reiterated | Strong Buy | 2025-01-14 | $32.00 | +776.70% |
Wedbush | Reiterated | Outperform | 2024-03-11 | โ | โ |
William Blair | Downgraded | Outperform โ Market Perform | 2023-09-20 | โ | โ |
Goldman Sachs | Downgraded | Buy โ Neutral | 2022-04-03 | โ | โ |
Stifel | Downgraded | Buy โ Hold | 2022-03-31 | โ | โ |
SVB Leerink | Downgraded | Outperform โ Market Perform | 2022-03-31 | โ | โ |
JonesTrading | Downgraded | Buy โ Hold | 2022-03-31 | โ | โ |
HC Wainwright & Co. | Downgraded | Buy โ Neutral | 2022-03-31 | โ | โ |
Institution
Leerink Partners
Reiterated ยท Outperform ยท 2026-08-13
$15.00
+311.00%
Cantor Fitzgerald
Reiterated ยท Overweight ยท 2026-05-28
$30.00
+721.90%
Raymond James
Reiterated ยท Strong Buy ยท 2025-01-14
$32.00
+776.70%
Wedbush
Reiterated ยท Outperform ยท 2024-03-11
โ
โ
William Blair
Downgraded ยท Outperform โ Market Perform ยท 2023-09-20
โ
โ
Goldman Sachs
Downgraded ยท Buy โ Neutral ยท 2022-04-03
โ
โ
Stifel
Downgraded ยท Buy โ Hold ยท 2022-03-31
โ
โ
SVB Leerink
Downgraded ยท Outperform โ Market Perform ยท 2022-03-31
โ
โ
JonesTrading
Downgraded ยท Buy โ Hold ยท 2022-03-31
โ
โ
HC Wainwright & Co.
Downgraded ยท Buy โ Neutral ยท 2022-03-31
โ
โ
One row per institution ยท price target from the firm's latest published target